ArticleThe oncologist2018
Pretreatment
Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase Ⅱ Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Paclitaxel (GT) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Glucose metabolic reprogramming: a novel strategy to enhance radiotherapy response to triple-negative breast cancer.Frontiers in public health · 2026Review
- Inter- and intra-tumoral heterogeneity on [EJNMMI reports · 2024Article
- Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.Journal of clinical medicine · 2023Review
- PretreatmentCancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Evaluation of tumour heterogeneity byBreast cancer research : BCR · 2022Article
- Article
- Heterogeneity derived fromCancer medicine · 2022Article
- Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- The progress of multimodal imaging combination and subregion based radiomics research of cancers.International journal of biological sciences · 2022Review
- Prognostic Value of Heterogeneity Index Derived from BaselineFrontiers in oncology · 2022Article
- PretreatmentAnnals of nuclear medicine · 2021Article
- Intratumoral Metabolic Heterogeneity and Other QuantitativeRadiology. Imaging cancer · 2021Article
- Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.International journal of general medicine · 2021Article
- Heterogeneous parameters based onQuantitative imaging in medicine and surgery · 2021Article
- Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams.International journal of molecular sciences · 2020Article
- CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.Molecular carcinogenesis · 2020Article
- PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.European journal of nuclear medicine and molecular imaging · 2019Article
- Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer.Cancer medicine · 2019Article
- Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a "PET biopsy" method.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntratumoral heterogeneity of MATERIALS AND
methodsmTNBC patients from three clinical trials (NCT00601159, NCT01287624, and NCT02341911) with whole-body
resultsA total of 42 mTNBC patients were included in this study. The median PFS of patients with high HI-T (>1.9) and high MAX-T (>10.5) was significantly shorter than patients with low HI-T (<1.9;
conclusionHI and MAX measured among metastatic lesions on pretreatment IMPLICATIONS FOR PRACTICE: Intratumoral heterogeneity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.